Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abetted, absent, accommodate, agonist, aided, Allergan, animal, announcement, antigen, ATPase, automatically, BCMA, bio, bioavailable, bluebird, bowel, bridge, Cacioppo, CAR, chimeric, China, closure, consummated, destroy, drawn, enjoining, entry, eosinophilic, Epizyme, goal, Hasnain, HMT, IPR, Juno, Kadin, kinase, knowhow, Lycera, merger, merit, met, modulator, month, narrowed, North, ozanimod, persistence, pinometostat, plasma, predefined, purported, receptor, rescission, RORy, Rosenberg, satisfaction, Scott, sphingosine, Strix, surface, switch, syndicated, tender, territory, Teva, unchanged, waiting, warrant, world
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.27 Exhibit 10.27 Letter Agreement with Scott a Smith
- 10.5 Exhibit 10.5 Celgene Corporation 2008 Stock Incentive Plan
- 31.1 Exhibit 31.1 Certification of the CEO Section 302
- 31.2 Exhibit 31.2 Certfication of the CFO Section 302
- 32.1 Exhibit 32.1 Certification of the CEO Section 906
- 32.2 Exhibit 32.2 Certification of the CFO Section 906
- Download Excel data file
- View Excel data file
Related press release
CELG similar filings
Filing view
External links
Exhibit 10.27
Summary of 2015 Compensation Package
Name | Scott A. Smith | |||||
Job Title | President, Inflammation & Immunology | |||||
Base Salary | $650,000 | Effective March 1, 2015 | ||||
Bonus Target | 75% | Effective January 1, 2015 | ||||
Annual Equity Award | Stock Options | Performance Stock Units | Restricted Stock Units | Effective February 17, 2015 | ||
Threshold | Target | Maximum | ||||
34,500 | 3,100 | 6,200 | 12,400 | 3,500 | ||
Severance Benefit | Lump sum 12 months of base salary Lump sum 12 months of bonus at target 12 months COBRA benefit at active employee rates, less applicable taxes | In the event of involuntary termination for reasons other than cause | ||||
"Double Trigger" due to Change in Control | All severance benefits Unvested RSUs and Options would fully vest Change in control payments would be reduced to avoid 280G excise tax, if beneficial to employee | In the event of position elimination due to change in control | ||||
Financial Planning Benefit | Up to $15,000 per year | Reimbursement of reasonable and customary fees associated with financial planning and/or tax preparation/advice |
Acknowledged and agreed: | On behalf of Celgene Corporation: | |||||
/s/Scott A. Smith | July 27, 2015 | /s/Robert J. Hugin | July 27, 2015 | |||
Scott A. Smith | Date | Robert J. Hugin | Date |